# HARROW, INC. (HROW) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_e48e181daafeb8e781fb · retrieved 2026-08-12T06:56:37.870Z

## Overview
Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products addressing conditions affecting the front and back of the eye, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface conditions.

On August 3, 2026, Harrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg, a cholinergic agonist for dry eye disease treatment. The Company will pay Viatris $30,000,000 in cash at closing and up to an additional $70,000,000 in contingent milestone payments if specified annual net sales thresholds are achieved in certain calendar years following the closing. The acquisition includes the related new drug application, regulatory approvals, intellectual property, developed technology, inventory, and certain related contracts. Harrow expects to fund the upfront cash payment using cash on hand, and the transaction is expected to close in the second half of 2026, subject to customary closing conditions.

## Terms
- Counterparty: Viatris Inc. · Deal value: $100.0M · Consideration: cash

## Key dates
- Announced 2026-08-06 · Expected close 2026-12-31

## Timeline
- 2026-08-06 · 8-K (0001493152-26-036256): 8-K - HARROW, INC. — *Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products addressing conditions affecting the front and back of the eye, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface conditions.* On August 3, 2026, Harrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg, a cholinergic agonist for dry eye disease treatment. The Company will pay Viatris $30,000,000 in cash at closing and up to an additional $70,000,000 in contingent milestone payments if specified annual net sales thresholds are achieved in certain calendar years following the closing. The acquisition includes the related new drug application, regulatory approvals, intellectual property, developed technology, inventory, and certain related contracts. Harrow expects to fund the upfront cash payment using cash on hand, and the transaction is expected to close in the second half of 2026, subject to customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/1360214/0001493152-26-036256.txt

## Citations
- 0001493152-26-036256 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226036256